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Abstract 
Aims 
The aims of this thesis were to investigate herd level risk factors for heifer clinical 
mastitis and to test the efficacy of a pre-calving intervention on prevalence of post-
calving IMI, incidence of clinical mastitis and somatic cell count (SCC) in heifers. 
Materials and methods 
A prospective survey ( chapter 3) was used to collect data concerning farmers ' 
management practices for rearing heifers and mastitis management. A proportion of 
herd-owners (n=250) subsequently provided data on the clinical mastitis cases in their 
herd occurring in the first 120 days of the subsequent lactation. 
A pilot quarter level intervention study (n=I 000 quarters; chapter 4) investigated the 
effect of pre-calving infusion of a teat sealant. Glands were randomly assigned to one 
of 4 treatment groups (no treatment; mammary gland secretion collection; infusion of 
a teat sealant; or sample collection with infusion of teat sealant) to identify the risk of 
each of these treatments on post-calving IMI and clinical mastitis. 
A heifer level intervention study (n= l 000 heifers; chapter 5, 6) investigated the pre-
calving use of teat sealant infused into all four quarters and/or treatment with the 
injectable antibiotic tylosin . Analysis was undertaken at quarter level ( chapter 5) and 
heifer level (including SCC data; chapter 6). 
Results 
The survey identified that the cumulative incidence of heifers with clinical mastitis 
was higher in herds with a higher per cow milk production, with more cows milked 
per person, in herds with a higher stocking rate, and in herds with a higher cumulative 
incidence of clinical mastitis in their multiparous cows. The cumulative incidence of 
heifers in a herd with clinical mastitis was lower in herds that managed the lactating 
cows in multiple groups. 
The pilot study found that the presence of an IMI pre-calving increased the risk of an 
IMI post-calving and the incidence of clinical mastitis, relative to no IMI pre-calving. 
Infusion of the teat sealant reduced the risk of post-calving IMI due to Streptococcus 
uberis and the incidence of clinical mastitis. Sampling the glands pre-calving had no 
effect on post-calving IMI or on incidence of clinical mastitis. 
The large-scale intervention study found that neither infusion of a teat sealant nor 
treatment with the injectable antibiotic increased the risk of cure of pre-calving IMI. 
Infusion of the teat sealant reduced the risk of quarter level new IMI. At both quarter 
and heifer level teat sealant reduced the risk of the prevalence of post-calving IMI, 
incidence of clinical mastitis. At heifer level the SCC was decreased throughout 
lactation following the use of a teat sealant. Tylosin had no effect on prevalence of 
IMI, incidence neither of clinical mastitis nor on SCC. 
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Conclusions 
It was concluded that the risk of heifer clinical mastitis was associated with a number 
of herd level management factors and that further studies are required to elucidate the 
mechanisms behind these associations. Hence, it may be possible to reduce the 
incidence of clinical mastitis in heifers by modification of herd level management 
practices. Intervention with an intramammary teat sealant pre-calving decreased the 
incidence of new infections over this high-risk peripartum period, and may provide a 
useful tool for reducing the risk of subclinical and clinical mastitis in heifers. 
3 
Acknowledgements 
Sometimes an opportunity arises before us, apparently out of nowhere and we take it, 
because it 'feels right', despite the fact there are some sacrifices that we know we are 
going to have to make because of it. Then, as the consequences and experiences that 
come about because of this opportunity surpass all expectations and far exceed your 
greatest hopes, you know that you WERE supposed to take that opportunity and you 
ARE where you are meant to be right now. 
Well this is definitely true for me taking on not only my MVS, but also the challenge of 
leaving my family and friends in Australia and coming to Animal Health Centre to 
work. If it wasn't for being able to do my MVS part-time and do clinical work par/-
time, I probably wouldn't have crossed the Tasman 3 and a bit years ago. Therefore I 
am forever grateful to Jock Macmillan and Ivan Caple for recommending me to the 
AHC and for suggesting the possibility of research 6 years ago, and of course to Scott 
McDougall and Ron Gibson for having the faith to take me on, and create a position 
for me within the research and clinical teams. 
I am the first to admit (and to all my friends and family it will be a broken record and 
I'm sorry) that despite the fact that I was sure I could thrive doing both research and 
clinical work in parallel it has been more difficult than I anticipated. The desire to 
please the immediate and friendly client with an urgent query, always disrupts the 
thought process at the most inopportune time, and in doing so increases the time 
required to do a simple piece of data analysis/appraisal of an article. SO I have to say 
a huge thank you to all the staff in the various clinical teams (Morrinsville, Te Aroha 
and Matamata) that I have been a part of over the last 3+ years. Especially to Jade, 
Rachel, Jan and Rhonda who have made a huge effort to support my need for 
research days/afternoons even in the height of spring, and who tirelessly listened to 
my various whinges and moans about assignments, statistics programmes and article 
rewrites. To Paula in Matamata who has been an absolute star to work with over the 
past 9 months, who has accommodated my need to spend the last 3 months writing up 
without one word of complaint - you have no idea how much that has meant to me! 
And to my clients, thank you for always being excited to hear about my latest heifer 
mast it is idea or results from the latest trial, and accepting my absence at times, thank 
you for asking me questions because it is your questions that drive my research, and I 
am doing this for you and your cows. 
A big thanks to the research team; to Chris Compton for your willingness to help with 
data analysis, project design, and your attention to detail which has led to the high 
quality example you have set with your MVS dissertation. To Fiona Anniss for your 
commitment to the team, your enthusiasm toward the heifer trials, your organisational 
skills and initiative when doing your tech duties - needless to say the work in this 
thesis couldn't have been done without your input. To Kathryn Berry for your 
entertainment value, enthusiasm, motivational ability and for being a vital part of the 
team. To Werner Hennig, my computer life saver, who always has time for my 
annoying computer questions after 5pm on Fridays, and of course to all the other 
people who have contributed to parts of the trials in this thesis- Rhonda Cooper, 
4 
Elizabeth Blythe, Mike Kingstone, Shelley Roberts, Judith Forno and Helena 
Habgood. 
To Scott, Fiona, Islay and Faye McDougall thank you for helping to make New 
Zealand my home; to Scott for supporting me while I learn, for listening to my ideas, 
for giving me the opportunity to do my MVS, encouraging my desire to travel to the 
UK for 3 months, and to present at World Buiatrics in Quebec and at DCV conference 
in Cairns, and for giving me a great grounding in dairy research - it has been a 
privilege to have you as a supervisor; to Fiona for editing my papers and being a 
person to vent to in times of frustration and to the girls for keeping me sane. 
Thanks to groups that provided financial assistance for these studies without you 
these questions would not have been answered; Animal Health Centre, Eltham 
District Veterinary Club, Dairy Insight, Elanco and Pfizer. 
Thanks to Andrew Bradley's group at Bristol Vet School for supporting me and 
creating a 3-month project in 2004, in which I was lucky enough to gallivant around 
the English and Welsh country-side with a plate meter in the name of dairy research. 
The work from that study is past the scope of this thesis but what I learnt from you 
and your team (particularly you, Jon Huxley and James Breen) has been invaluable 
and I look forward to continued collaboration with you all. Thanks also to the 
University of Melbourne for the Barrenger Overseas Scholarship for making this trip 
possible. 
The crew at the Massey Epicentre has been brilliant- Cord Heuer you have been great 
supervisor to bounce ideas off, and to improve my lateral thinking. Thanks for 
replying so efficiently to my constant stream of emails, and providing the often-needed 
positive spin on data when things aren't looking to great! To the others at the 
epicentre, thank you for your efforts, not just from me but from all the external 
students doing the block Epidemiology papers - the time you spend organising the 
courses for us, does not go unnoticed and we do appreciate your enthusiasm - Mark 
Stevenson, Nigel Perkins (now moved on), Julie and Colleen. 
Thanks to Scott, Cord, Chris, Denise and Kyna for the vast amounts of editing 
required to complete this thesis. 
To my family and friends (you know who you are I hope), flatmates at various times 
(including Basil, Felix and Flash) who have supported me during my MVS and home 
relocation, who have been neglected at times due to hours/day issues - thank you so 
much, I am eternally grateful for your support, advice, reality checks and criticism as 
needed. And of course a huge thank you to Adrian for constantly listening to my latest 
research drama without complaint, bringing me back down to earth as required, 
reminding me that I don't have to be busy I 10% of the time, and that "sleep is NOT 
something I can do when I'm dead" and for accepting me for who I am. So at the 
completion of my MVS what can I say ... 
"We also rejoice in our sufferings, because we know that suffering produces 
perseverance; perseverance, character; and character, hope." Romans 5:3 
So glad you got to see it finished MUM! 
5 
Table of contents 
ABSTRACT ................................................................................ .............................. 2 
AIMS .......................................................................................................................... 2 
MATERIALS AND METHODS ........................................................................................ 2 
RESULTS .................................................................................................................... 2 
CONCLUSIONS ............................................................................................................ 3 
ACKNOWLEDGEMENTS ..................................................................................... 4 
TABLE OF CONTENTS ......................................................................................... 6 
TABLE OF FIGURES ........................................................................................... 11 
TABLE OF TABLES ............................................................................................. 14 
CHAPTER 1 LITERATURE REVIEW ON HEIFER MASTITIS IN DAIRY 
HEIFERS ................................................................................................................ 19 
INTRODUCTION ........................................................................................................ 19 
REVIEW ................................................................................................................... 20 
EPIDEMIOLOGY OF HEIFER MASTITIS ...................................................................... 20 
BACTERIOLOGY OF MASTITIS IN HEIFERS ................................................................ 22 
RISK FACTORS FOR MASTITIS IN HEIFERS ................................................................ 22 
Herd level risk factors for heifer mastitis ..... .. .. .... .. ... .. ... ..... ..... ..... ........ ....... .... ......... 22 
Heifer level risk factors for mastitis ......... .... ....... .. ............. .. ... .. .. .. ......... ...... ......... .. .. 23 
Effect of existing intramammary infection on risk of new intramammary infection .. 25 
6 
MANAGEMENT OF HEIFER MASTITIS ........................................................................ 27 
Reducing the intramammary infection pre-calving ................................................... 27 
Reducing the risk of new intramammary infection in heifers .................................... 29 
Improving immunity of cows to decrease intramammary infection ........................... 31 
ECONOMICS OF MASTITIS ........................................................................................ 32 
SUMMARY ................................................................................................................ 33 
REFERENCES ....................................................................................... ... 34 
CHAPTER 2 STATISTICAL METHODS TO ACCOUNT FOR 
CORRELATION WITHIN GROUPS .................................................................. 42 
REFERENCES ............................................................................................................ 45 
CHAPTER 3 DAIRY HEIFER MANAGEMENT AND ITS RELATIONSHIPS 
WITH INCIDENCE OF CLINICAL MASTITIS ................................................ 46 
ABSTRACT ............................................................................................................... 46 
AIMS: ... .. .. ..... ........................... .... ......... .... ............................................................... 46 
MATERIALS AND METHODS: .. .. ................. .... ...... .............. ................................. .. 46 
RESULTS: ....................................... .............. .................................. ... ... ............ ... .... 46 
CONCLUSIONS: ..................................................................................................... 46 
CLINICAL RELEVANCE: ............................... .. .. ... .......... ... .............................. .. ..... 46 
KEYWORDS: .................................................. ................. ... ...... .. .............. ............... 46 
ABBREVIATIONS: ................................................................................................... 46 
INTRODUCTION ........................................................................................................ 47 
MATERIALS AND METHODS ..................................................................................... 48 
DATA HANDLING AND STATISTICAL ANALYSIS ................................................................ .49 
7 
RESULTS .................................................................................................................. 51 
BIVA RIATE ANA LYSIS .. ...... . ... . .... . . ... ... . ..... . .. . .... ...... ....... . .. . ... .. .. .... .. .... .. ..... .. .. . ... . .......... 52 
MULTIVARIATE ANA LYSIS .................................... . .. . .............. . ........ .. ................... . . . ...... 52 
DISCUSSION ............................................................................................................. 52 
CONCLUSIONS •••••••••••••••••••••••••.••••••••.•••••••••••• •• •••••••••••••• •.••••••••••• •• ••••..•.• ••••••••••••..••••• 57 
ACKNO\\'LEDGEJ',,1ENTS ............................................................. . .... . ......................... 57 
REFERENCES ............................................................................................................ 66 
CHAPTER 4 SUBCLINICAL AND CLINICAL MASTITIS IN HEIFERS 
FOLLOWING THE USE OF A TEAT SEALANT PRE-CALVING .................. 69 
ABSTRACT ............................................................................................................... 69 
INTRODUCTION ............................................................................. . .......................... 70 
MATERIALS AND METHODS ...................................................................................... 71 
Bacteriology ........... ......................... .. ..... .... ........ .... .... ..... ...... ... ..... ..... .......... ..... .. ... . 72 
Statistical analysis .... .. ..... ...... ... .. .. ..... ..... .......... ....... ......... ..... .... .. ... ... ... ... .. ........ ... ... 72 
RESULTS .................................................................................................................. 74 
Objective 1 ..................................................................... ... ....... .. ...... .. ...... ................ 75 
Objective 2 .. ...... .... ...... .... .... .... ...... ... .. ... ..... .......... ..... ..... ... .... ... .. .... .. .... .. .... ... .... .. ... .. 75 
Objective 3 .... ............. ..... .... ..... .. .. .. ...... ........... ...... ..... ..... .. ..... .. ..... ..... .. ........ ..... .. .. ... 75 
Objective 4 .......................... ......... ................................................................. ... .... .... 75 
Objective 5 ..................... .............. ... .. ... ... ........... .. .. .. ........ .... .. .. ... .. ... ...... .... .. ............ 76 
Objective 6 ... ..... .......... .. ..... .. .. .. ....... ......... ...... ... .. .............................................. .... .. . 76 
DISCUSSION •••••••••••••••• •• •••••••••••••••••••..••••••••••••••••••••••••••••••••••••••••••••••.•..•••••••••••••••••••• 76 
Objective 1 .......................... ... ...... .. ................... .. ..... ... ... ............................. ............. 76 
Objective 2 ...... ... ... ...... .. ......... ............................... ..... .. ........ .......... ... ..... .... .............. 77 
8 
Objective 3 ............................................................................................................... 78 
Objective 4, 5 & 6 .................................................................................................... 78 
Other findings ......................................................................................................... 79 
CONCLUSIONS ............................................... .......... ................................... .............. 80 
ACKNOWLEDGEMENTS ........................................... ....... ............ ... ........ ................... 80 
CHAPTER 5 QUARTER LEVEL ANALYSIS OF SUBCLINICAL AND 
CLINICAL MASTITIS IN PRIMIPAROUS HEIFERS FOLLOWING THE 
USE OF A TEAT SEALANT AND/OR AN INJECT ABLE ANTIBIOTIC PRE-
CALVING .............................................................................................................. 92 
ABSTRACT ................................................................................. .............................. 92 
INTRODUCTION ........................................................................................................ 93 
MATERIALS AND METHODS ...................................................................................... 94 
Bacteriology .................................. .................. ... .. ............ ... .................................... 96 
Data Handling ........................................................................................................ . 96 
Data analysis ................................ .. ... ...................... ........... .. ......... .......................... 97 
RESULTS .................................................................................................................. 99 
Effect of treatment on cure of existing IM/.. .......................................................... . 99 
Effect of treatment on incidence of new /MI.. ........... ................................ .............. 99 
Effect of treatment on prevalence of IM/ post-calving .............. .. .. ........ .. .... .. ........ 100 
Effect of treatment on incidence of clinical mastitis ....... .. ...... .............................. 100 
DISCUSSION ........................................................................................................... 100 
CONCLUSIONS ........................................................................................................ 104 
REFERENCES ................ .......................... ... ............................................................. 115 
9 
CHAPTER 6 THE EFFECTS OF A TEAT SEALANT AND/OR AND 
INJECTABLE ANTIBIOTIC PRE-CALVING IN PRIMIPAROUS HEIFERS 
ON SUBCLINICAL AND CLINICAL MASTITIS AND SOMATIC CELL 
COUNTS ....... ....... ............. ............................................... ..................................... 118 
ABSTRACT ........................................................................... .... . .... .................... ... .. 118 
AIMS: ..... ..... .... ... ... .... .. ......... ............... .... ... ........................ ... .. ....... ... .. .. ... .............. 118 
MATERIALS AND METHODS: ...... .. ... ....... ................. .. .. ....... .. .... ...... ... ... .... ... ....... 118 
RESULTS: .......... ....................................................... ................ ... ..... .................... . 118 
CONCLUSIONS: .... ..... ..... ....... ....... .... .... ...... .... .... .... ..... ..... ....................... .. .......... 118 
CLINICAL RELEVANCE .... ... ...... .... .. ...... ... ..... ..... ..... ....... .. .. .. ... ...... ..... .. ............... 118 
INTRODUCTION ........................................... ..... ..... .... ............................................. 119 
MATERIAL AND METHODS ..................................................................................... 120 
Bacteriology ................. ......................... ................................ ................. ............... 122 
Data Handling .. .... .... .. ...... .... ................ .... ......................... .. ... .. ... ... .. ... .......... ..... ... 123 
Data Analysis ..... .......... .... ... ........... ...... ........................... .... .. .... .... ........ ........... .... . 123 
RESULTS ..................................................... .... . ...... .... ....... ............. ........... ............. 125 
DISCUSSION ........................................................................................................... 126 
CONCLUSIONS ............................................................................ . ........................... 129 
ACKNOWLEDGEMENTS FOR CHAPTER 5 AND 6 ...................................................... 129 
REFERENCES ... . ...................................................................................................... 135 
REFERENCES .......................................................................................................... 136 
CHAPTER 7 DISCUSSION ................................................................................ 140 
APPENDIX 1 HEIFER SURVEY QUESTIONNAIRE ...................................... 142 
10 
APPENDIX 2 ........................................................................................................ 145 
Table of Figures 
Figure 1 From (Barkema et al 1998c). Distribution of the incidence rate of clinical 
mastitis (IRCM) relative to the day of calving for heifers and older cows ...... . 21 
Figure 2 The mean (SEM) herd (n =250 herds) proportion of heifers (grey) and cows 
(white) diagnosed with lactational clinical mast it is from calving to approximately 120 
days into lactation for each calendar month. The proportion of cases of clinical 
mastitis/herd for cows and heifers was compared using chi-squared analysis, the 
significantly different proportions are indicated * (p <0. 05) . ............... ...... .... .. ...... ... 58 
Figure 3 Predicted proportions (SEM) of heifers with clinical mastitis over the first 
120 days of lactation for ranges of percentage of cows in a herd with clinical mas ti tis 
during the first 120 days of lactation. The predicted proportions were adjusted for 
mean production of milk solids (i.e. 270 kg MS /cow/lactation), mean number of cows 
per person milking (i.e. 170 cows/person), single milking mob and in the Waikato 
region. The trendline represents linear line of best fit ........................ .. .................... . 59 
Figure 4 Predicted proportions (SEM) of heifers with clinical mastitis over the first 
120 days of lactation for the average number of cows per person milking. The 
predicted proportions were adjusted for mean production of milk solids (i.e. 270 kg 
MS/cow/lactation), mean herd proportion of cows with clinical mastitis of 7. 7-13.4%, 
single milking mob and in the region Waikato. The trendline is the linear line of best 
fit for the model ............. .. ......................................................................................... 60 
Figure 5 Predicted proportions (SEM) of heifers with clinical mastitis over the first 
120 days of lactation for average milk production per herd (i.e. kg milk 
solids/cow/lactation calculated using farm production for the 2002/2003 
season/number of cows at the start of the 2003/2004 season). The predicted 
11 
proportions were adjusted for mean herd proportion of cows with clinical mastitis of 
7. 7- 13.4%, average number of cows/person milking (i.e. 170 cows/milkers), a single 
milking mob and in the region Waikato. The trendline is the linear line of best fit from 
the model. .......................................................................... .. ... ... ..... ...... .. ... ........ .... ... 61 
Figure 6 The four treatment allocations randomly assigned to groups of four 
sequentially presented heifers within a herd. Each large box represents the four 
glands within a heifer with the smaller boxes one of the four glands, clockwise from 
top left; left front, right front, right rear, left rear. TS= teat sealant infused, S=sample 
taken, S+ TS = sample taken and teat sealant infused, C=control ......... ..... ... .. ........ 86 
Figure 7 Mean (± SEM) prevalence as a percentage of glands with intramammary 
infection (IM!) by day post-calving at milk sampling. ..... ......... ........... .. ..... ... ............ 87 
Figure 8 The cumulative incidence of clinical mastitis (±SEM) within herd from which 
any pathogen was isolated by week of calving relative to the median calving week for 
heifers within a herd. .... .... ............... ...... ........................ .. ........ .. ........ .. ..................... 88 
Figure 9. Prevalence of glands with intramammary infection (!Ml) post-calving (%) 
by day at sampling. ..... .. ........ ... ... ..... ...... ... ... ......... .......... .. ....... ................ ..... ......... 111 
Figure 10. Raw gland level prevalence of post-calving intramammary infection (IMI; 
%) (dotted) and relative risks (RR) of post-calving IMI calculated from the final 
model (so lid line), by body condition score day 0-5 post-calving. ............. ... ...... ..... 112 
Figure 11. Incidence of new intramammary infection (JMI) (%) of any pathogen by 
minimum teat height for all glands, with a linear trend line fitted through the raw 
data . ................ ....... .. ....... ................ .... .......................... ....................... .. ............ .... 113 
Figure 12. Raw gland level incidence of clinical mastitis (%) occurring within the 
first 14 days after calving that cultured any pathogen by treatment group (infusion of 
12 
all glands with teat sealant (grey) or untreated glands (white)) , blocked by the pre-
calving !MI status for each gland. .... ........ ..... .. ...... ..... .. ...... ........ ..... ....................... 114 
Figure 13. Predicted somatic cell counts (SCC) from the final model in heifers 
throughout lactation following treatment approximately 39 days pre-calving with 
infusion of teat sealant in all four quarters within heifers ( ) or no treatment with 
teat sealant ( ) ............................................ ....... .... ...... ........... .. ........................ . 135 
13 
Table of Tables 
Table 1 From (Barkema et al 1997). Variance components and intraclass correlation 
(ICC) for infected quarters within cow and within herd ICC >0.2 is considered large 
enough to require analysis to account/or clustering of the data ... .... .. ...... ... .. ..... ..... .43 
Table 2 Number of herds (n=250) in which potential risk factors (variables) for 
clinical mastitis in each level for the categorical variables, the bivariate odds ratio 
(OR) and bivariate probability (P) that that variable was associated with the 
proportion of heifers in a herd with clinical mastitis ... ...... .. ............ ... ........ .. .. ... ... ..... 62 
Table 3 Descriptions (mean, standard deviation (Std Dev), minimum (min), maximum 
(max) and number of herds (n)) , bivariate odds ratio (OR) and bivariate probability 
(p) for potential risk factors that were continuous variables for the proportion of 
heifers with clinical mast it is . .. ..... ......... ........ ............ ... .... ....... .......... ....... ... .. ...... ... ... 64 
Table 4 Odds ratios (OR) and 95% confidence intervals (CJ) with probability values 
(p) calculated from the multivariate final model for the outcome variable proportion 
of heifers with clinical mastitis in a herd. .. ..... .. ...... ..... ...... .. ...... .. ... .... .. .... ............... . 65 
Table 5 Count (n) and percentage (%) of glands with intramammary infection (/Ml) 
on average 31 days before the start of a seasonal calving period pre-calving for 
glands, which were sampled with no further treatment (SJ or sampled and then 
infused with a teat sealant (TS+S) . ... ... ... ........ .. .... ........ ..... .... ....... .. ..... ..................... 81 
Table 6 Count (n) and percentage (%) of glands with intramammary infection (/Ml) 
within 4 days after calving for glands within heifers not sampled or treated (C), 
infused with a teat sealant (TS) pre-calving, sampled only pre-calving (SJ or sampled 
and infused with a teat sealant pre-calving (S+ TS) .. ................. .. ........... .... ....... ...... .. 82 
Table 7 Count (n) and percentage (%) of bacteriological glands within all clinical 
mastitis glands from heifers diagnosed from 3 days before to 14 days post-calving, 
from glands treated approximately 31 days before the start of a seasonal calving 
14 
programme with nothing (C), infused with a teat sealant (I'S) pre-calving, sampled 
only (S) or sampled and infused with a teat sealant (S+ TS) . ... ... .... ..... ...... ...... .... ...... 83 
Table 8 Relative risks (RR) from the multivariate analyses and 95% confidence 
intervals (CI) with probability values (P) calculated from the final logistic regression 
models for the dependent variables. Models 1-5 include pre-calving bacteriology 
status (n =503) as a variable in the model, models 6-10 do not (n=J006). Herd is 
included in all models as a fixed effect. Days from calving to sampling were included 
as a categorical variable in all post-calving IMI models (models 1-3, 6-8) and days 
calved relative to the group median calving date in the clinical mastitis models 
(models 4-5, 9-10). ........ .... .. ... ... .. ......... ........... ..... ...... ........ .... ...... ...... ........ .. .... ... ... .. 84 
Table 9 Crude relative risks (RR) with 95% confidence intervals (CI) and probability 
values (P) for the outcome post-calving intramammary infection (!MI), in the 
presence or absence of a pre-calving IMI with coagulase-negative staphylococcus 
(ens) .... ....... ...... .... .. ..... ...... ..... ......... ..... .. ... .. ... ...... .... ....... ........... .... ...... .. ... ...... .... ... .. 85 
Table I 0. Number and percentage (within treatment group) of bacterial species 
isolated from the mammary gland secretion collected on average 39 days before 
calving from 4164 glands from heifers subsequently treated with injectable tylosin (5g 
for 3 days at 24 hourly intervals), or infused with an intramammary teat sealant into 
all 4 glands (teat sealant), or treated with injectable tylosin (5g for 3 days at 24 
hourly intervals) and infused with an intramammary teat sealant into all 4 glands 
(teat sealant and tylosin) or nothing (control) ................. ........... ................... ....... ... I 05 
Table 11. Number and percentages (within treatment group) of bacterial species 
isolates from the glands sampled by 0 and 5 days after calving (n=4 I 64 glands) from 
heifers subsequently treated with injectable tylosin (5g for 3 days at 24 hourly 
intervals), or infused with an intramammary teat sealant into all 4 glands (teat 
15 
sealant), or treated with injectable tylosin (5g for 3 days at 24 hourly intervals) and 
infused with an intramammary teat sealant into all 4 glands (teat sealant and tylosin) 
or nothing (control) . ... ..... ...................... ... .... .......... ...... ........ ..... ......... ... ...... ... ... ..... I 06 
Table I 2. Number and percentage of bacterial species isolated from glands diagnosed 
with clinical mastitis I 4 days post-calving within treatment group from heifers 
subsequently treated with injectable tylosin (5g for 3 days at 24 hourly intervals), or 
infused with an intramammary teat sealant into all 4 glands (teat sealant), or treated 
with injectable tylosin (5g for 3 days at 24 hourly intervals) and infused with an 
intramammary teat sealant into all 4 glands (teat sealant and tylosin) or nothing 
(control) . ................... .... ......... ...... ........ ...... .... ............. .................. ... .......... ..... ....... I 07 
Table I 3. Relative risk (RR) and 95% confidence intervals (CJ) and probability values 
(P) of post-calving IM! for heifers treated with injectable tylosin (5g for 3 days at 24 
hourly intervals) or infusion of an intramammary teat sealant into all 4 glands, 
approximately 39 days pre-calving .... ..... .... ................ ... .. ... .. ..... .. ........................... I 08 
Table I 4. Relative Risk (RR) and 95% confidence intervals (CJ) for new 
intramammary infection (!MI) with any pathogen between approximately 39 days pre-
calving and 0-5 days post-calving in heifers treated with injectable tylosin (5g for 3 
days at 24 hourly intervals) or infusion of an intramammary teat sealant into all 4 
glands, approximately 35 days pre-calving. ...... ........... ..... ...................................... I 09 
Table I 5. Relative risk (RR) and 95% confidence interval (CI) of glands being 
diagnosed with clinical mastitis up to I 4 days post-calving from which bacterial 
pathogens were isolated in heifers treated with injectable tylosin (5gfor 3 days at 24 
hourly intervals) or infusion of an intramammary teat sealant into all 4 glands, 
approximately 39 days pre-calving. .... .. .... .... ..... .... ..... .. ...... .. ... ... ... .. ............. .......... I JO 
16 
Table 16. Number of heifers treated (n), calving date, breed, prevalence of 
intramammary infection (IM!) pre and post calving, cumulative incidence of clinical 
mastitis (%) in the first 2 weeks post-calving, milk solids production (fat + protein 
kg/cow Id) and geometric mean SCC at each of the herd tests for heifers treated with 
infusion of teat sealant into all 4 glands (Teat sealant), treatment with 3 X 5g of 
parenteral tylosin (Tylosin) , both infusion of a teat sealant and tylosin treatment (Teat 
sealant and tylosin) or with nothing (Control) ~ 39 days before calving. ... .... .... .. .. . 130 
Table 17. Number of quarters (n) per heifer diagnosed with clinical mastitis and of 
those the number and percentage of quarters per heifer that isolated no bacteria for 
heifers treated with infusion of teat sealant into all 4 glands (Teat sealant), treatment 
with 3 X 5g of parenteral tylosin (Tylosin), both infusion of a teat sealant and tylosin 
treatment (Teat sealant and tylosin) or with nothing (Control) ~ 39 days before 
calving . .......... ... .......... .. .. ........... ... .. ......... ... .. ........... ......... .. ......... ... .... .. ... .. ... .... .. ... 131 
Table 18. Relative risk (RR) and 95% confidence intervals (CI) of post-calving 
intramammary infection (!MI) for heifers treated approximately 39 days pre-calving 
with nothing (Control,· 243 heifers), infusion of teat sealant in all four quarters (teat 
sealant,· 246 heifers) or injection of 5 g of tylosin on 3 occasions at 24 h intervals 
(tylosin,· 246 heifers) or with both infusion of teat sealant in all four quarters and 
injection of 5 g of tylosin on 3 occasions at 24 h intervals (teat sealant and tylosin,· 
246 heifers) calculated from the multivariate analysis .......... .. ........ ....... ... .............. 132 
Table 19. Relative risk (RR) and 95% confidence intervals (CI) of clinical mastitis 
diagnosis for heifers treated approximately 39 days pre-calving with nothing 
(Control; 243 heifers), infusion of teat sealant in all four quarters (teat sealant; 246 
heifers) or injection of 5 g of tylosin on 3 occasions at 24 h intervals (tylosin; 246 
heifers) or with both infusion of teat sealant in all four quarters and injection of 5 g of 
17 
tylosin on 3 occasions at 24 h intervals (teat sealant and tylosin; 246 heifers) 
calculatedfrom the multivariate analysis ....... ........ ............ .. .. ...... .......... ...... .......... 133 
Table 20. Factors affected somatic cell counts (SCC) in heifers following treatment 
approximately 39 days pre-calving with nothing (Control; 243 heifers), infusion of 
teat sealant in all four quarters (teat sealant; 246 heifers) or injection of 5 g of tylosin 
on 3 occasions at 24 h intervals (tylosin; 246 heifers) or with both infusion of teat 
sealant in all four quarters and injection of 5 g of tylosin on 3 occasions at 24 h 
intervals (teat sealant and tylosin; 246 heifers) calculated from the multivariate 
analysis . .......................................... ... ............ ........... ...... ..... ........ .... ..... .. .............. . 134 
18 
